NVIDIA launches Jetson Thor robotics computers for physical AI systems
Investing.com -- Sanofi (NASDAQ:SNY), the French multinational pharmaceutical company, has opted to extend its license with Nurix Therapeutics Inc’s STAT6 program.
This move makes Nurix eligible for $465 million in potential milestones and royalties. In addition, Nurix is set to receive a $15 million license extension fee from Sanofi.
Nurix Therapeutics Inc, a biopharmaceutical company based in San Francisco, is focused on the discovery, development, and commercialization of small molecule therapeutics designed to control the human immune system.
The STAT6 program is one of the many initiatives undertaken by the company to advance the field of therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.